Oral manifestations in patients undergoing chemotherapy
Authors:
- Iandra Luah Souza MaiaIMIandra Luah Souza Maia
- Rosany Larissa Brito de OliveiraRORosany Larissa Brito de Oliveira
- Luiz Fernando Andrade MatosLMLuiz Fernando Andrade Matos
- Antônio Carlos MarquetiAMAntônio Carlos Marqueti
- Geydson Silveira da CruzGCGeydson Silveira da Cruz
- Álvaro Bezerra CardosoÁCÁlvaro Bezerra Cardoso
Open Access
- 18 July 2025
- journal article
- Published by Universidade Estadual de Campinas in Brazilian Journal of Oral Sciences
- Vol. 24, e257209
Abstract
The proposed treatment for malignant neoplasms can be isolated or combined, involving resective surgery, radiotherapy, chemotherapy, and/or hormone replacement. Chemotherapy induces extensive immunosuppression and affects both healthy and abnormal cells. This cytotoxicity from the treatment has a significant effect that can lead to changes in the oral mucosa. The severity is related to the type of drug, duration of treatment, dosage used, level of oral hygiene during treatment, and the individual’s age. Therefore, monitoring oral health before, during, and after antineoplastic therapy is essential. Aim: To evaluate the main oral manifestations that oncology patients presented before and after 15 days from the first administration of chemotherapy medication. Methods: A prospective observational study was conducted with 31 individuals treated at a Hospital Oncology and Hematology Service. The evaluations included the following steps: (1) Patient identification and completion of assessment forms; (2) Clinical examination of the oral cavity before and after the start of chemotherapy; and (3) Providing guidance to patients regarding oral care during oncological treatment. Results: It was observed that 70.96% of patients exhibited oral manifestations 15 days after the first infusion of antineoplastic drugs. The main changes identified included xerostomia and oral mucositis. Conclusion: Dental follow-up during chemotherapy is essential for preventing and managing potential oral emergencies, thereby avoiding interruptions in systemic treatment and ultimately enhancing the quality of life for these patients.Keywords
This publication has 21 references indexed in Scilit:
- Risk factors associated with prognosis of patients with medication‐related osteonecrosis of the jawHead & Neck, 2023
- American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 UpdateJournal of Oral and Maxillofacial Surgery, 2022
- Oral and dental health status in patients undergoing neoadjuvant chemotherapy for locally advanced head and neck cancerOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2021
- MUCOSITE E FÓRMULAS FARMACÊUTICAS MAGISTRAIS PARA USO EM PACIENTES EM CUIDADOS PALIATIVOS ONCOLÓGICOS: REVISÃO DE LITERATURAHematology, Transfusion and Cell Therapy, 2021
- MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapyCancer, 2020
- Prevalence of oral side effects of chemotherapy and its relationship with periodontal risk: a cross sectional studySupportive Care in Cancer, 2019
- Oral care during cancer treatmentThe Journal of the American Dental Association, 2019
- Changes in taste and smell function, dietary intake, food preference, and body composition in testicular cancer patients treated with cisplatin-based chemotherapyClinical Nutrition, 2017
- Prevalence of oral mucositis, dry mouth, and dysphagia in advanced cancer patientsSupportive Care in Cancer, 2015
- MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapyCancer, 2014